In addition to dietary and lifestyle modifications, early-stage disease patients are likely to be initiated on an oral antidiabetic, especially metformin, the first-line T2DM therapy, but in patients with progressed disease a combination glucose-lowering regimen composed of oral antidiabetic and parenteral insulin therapy is prevalently used3. This evidence concerns the gene INS and type 2 diabetes mellitus.